{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:33:16Z","timestamp":1790728396619,"version":"4.1.0"},"reference-count":33,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T00:00:00Z","timestamp":1666915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"German Cancer Aid","award":["70112447\/70112457"],"award-info":[{"award-number":["70112447\/70112457"]}]},{"name":"German Cancer Aid","award":["70114066\/70114067"],"award-info":[{"award-number":["70114066\/70114067"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Drug-related problems (e.g., adverse drug reactions, ADR) are serious safety issues in patients treated with oral anticancer therapeutics (OAT). The previously published randomized AMBORA trial showed that an intensified clinical pharmacological\/pharmaceutical care program within the first 12 weeks of treatment reduces the number and severity of ADR as well as hospitalization rates in 202 patients. The present investigation focused on unscheduled hospitalizations detected within AMBORA and analyzed the characteristics (e.g., frequency, involved OAT) and cost of each hospital stay. To estimate the potential savings of an intensified care program in a larger group, the absolute risk for OAT-related hospitalizations was extrapolated to all insureds of a leading German statutory health insurance company (AOK Bayern). Within 12 weeks, 45 of 202 patients were hospitalized. 50% of all unscheduled hospital admissions were OAT-related (20 of 40) and occurred in 18 patients. The mean cost per inpatient stay was EUR 5873. The intensified AMBORA care program reduced the patients\u2019 absolute risk for OAT-related hospitalization by 11.36%. If this care program would have been implemented in the AOK Bayern collective (3,862,017 insureds) it has the potential to reduce hospitalization rates and thereby cost by a maximum of EUR 4.745 million within 12 weeks after therapy initiation.<\/jats:p>","DOI":"10.3390\/jcm11216392","type":"journal-article","created":{"date-parts":[[2022,10,30]],"date-time":"2022-10-30T07:26:50Z","timestamp":1667114810000},"page":"6392","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Characteristics and Cost of Unscheduled Hospitalizations in Patients Treated with New Oral Anticancer Drugs in Germany: Evidence from the Randomized AMBORA Trial"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5772-4956","authenticated-orcid":false,"given":"Pauline","family":"D\u00fcrr","sequence":"first","affiliation":[{"name":"Pharmacy Department, Erlangen University Hospital, 91054 Erlangen, Germany"},{"name":"Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, 91054 Erlangen, Germany"},{"name":"Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Meier","sequence":"additional","affiliation":[{"name":"Department of Management and Economics, SRH Wilhelm L\u00f6he University of Applied Sciences, 90763 F\u00fcrth, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Schlichtig","sequence":"additional","affiliation":[{"name":"Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, 91054 Erlangen, Germany"},{"name":"Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Schramm","sequence":"additional","affiliation":[{"name":"AOK Bayern, 93055 Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Sch\u00f6tz","sequence":"additional","affiliation":[{"name":"AOK Bayern, 93055 Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0334-7478","authenticated-orcid":false,"given":"Martin F.","family":"Fromm","sequence":"additional","affiliation":[{"name":"Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, 91054 Erlangen, Germany"},{"name":"Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"D\u00f6rje","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Erlangen University Hospital, 91054 Erlangen, Germany"},{"name":"Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.6004\/jnccn.2008.2003","article-title":"NCCN task force report: Oral chemotherapy","volume":"6","author":"Weingart","year":"2008","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/bjc.2013.48","article-title":"Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs","volume":"108","author":"Brundel","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1016\/S1470-2045(18)30094-9","article-title":"Chemotherapy medication errors","volume":"19","author":"Weingart","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_4","first-page":"775","article-title":"New oral anti-cancer drugs and medication safety","volume":"116","author":"Schlichtig","year":"2019","journal-title":"Dtsch. \u00c4rzteblatt Int."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/cpt.2338","article-title":"Medication errors during treatment with new oral anticancer agents: Consequences for clinical practice based on the AMBORA study","volume":"110","author":"Schlichtig","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1200\/JCO.20.03088","article-title":"The randomized AMBORA trial: Impact of pharmacological\/pharmaceutical care on medication safety and patient-reported outcomes during treatment with new oral anticancer agents","volume":"39","author":"Schlichtig","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1200\/JOP.18.00319","article-title":"Role of adverse events in unscheduled hospitalizations among patients with solid tumors who receive medical oncology treatment","volume":"15","author":"Wong","year":"2019","journal-title":"J. Oncol. Pract."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1001\/jamaoncol.2015.0828","article-title":"A clinical prediction model to assess risk for chemotherapy-related hospitalization in patients initiating palliative chemotherapy","volume":"1","author":"Brooks","year":"2015","journal-title":"JAMA Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1093\/jnci\/djj305","article-title":"Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer","volume":"98","author":"Hassett","year":"2006","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/jop.2005.1.1.15","article-title":"Development of a patient registry to evaluate hospital admissions related to chemotherapy toxicity in a community cancer center","volume":"1","author":"Krzyzanowska","year":"2005","journal-title":"J. Oncol. Pract."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s00520-010-0913-y","article-title":"Chemotherapy outpatients\u2019 unplanned presentations to hospital: A retrospective study","volume":"19","author":"McKenzie","year":"2011","journal-title":"Support Care Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"618","DOI":"10.6004\/jnccn.2012.0063","article-title":"Oral chemotherapy program improves adherence and reduces medication wastage and hospital admissions","volume":"10","author":"Khandelwal","year":"2012","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3892\/mco.2020.2174","article-title":"Survey of serious adverse events and safety evaluation of oral anticancer drug treatment in Japan: A retrospective study","volume":"14","author":"Kawasumi","year":"2021","journal-title":"Mol. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"7174","DOI":"10.1002\/cam4.2559","article-title":"Treatment patterns, adverse events, healthcare resource use and costs among commercially insured patients with mantle cell lymphoma in the United States","volume":"8","author":"Kabadi","year":"2019","journal-title":"Cancer Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1080\/13696998.2017.1421546","article-title":"Healthcare resource utilization among patients with relapsed multiple myeloma in the UK, France, and Italy","volume":"21","author":"Yong","year":"2018","journal-title":"J. Med. Econ."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1007\/s12325-018-0774-1","article-title":"Treatment duration, healthcare resource utilization, and costs among chemotherapy-na\u00efve patients with metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate: A retrospective claims analysis","volume":"35","author":"Schultz","year":"2018","journal-title":"Adv. Ther."},{"key":"ref_17","first-page":"1140","article-title":"Tyrosine kinase inhibitors initiation, cost sharing, and health care utilization in patients with newly diagnosed chronic myeloid leukemia: A retrospective claims-based study","volume":"25","author":"Phuar","year":"2019","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1001\/jamaoncol.2019.0086","article-title":"Treatment-Related Complications of Systemic Therapy and Radiotherapy","volume":"5","author":"Jairam","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1007\/s00520-012-1711-5","article-title":"The impact of chemotherapy-induced side effects on medical care usage and cost in German hospital care\u2212an observational analysis on non-small-cell lung cancer patients","volume":"21","author":"Paessens","year":"2013","journal-title":"Support Care Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1200\/JOP.2015.004812","article-title":"ReCAP: Hospitalizations in older adults with advanced cancer: The role of chemotherapy","volume":"12","author":"Atoria","year":"2016","journal-title":"J. Oncol. Pract."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1634\/theoncologist.2010-0354","article-title":"Chemotherapy-related hospitalization among community cancer center patients","volume":"16","author":"Hassett","year":"2011","journal-title":"Oncologist"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1200\/JOP.2014.000257","article-title":"Emergency room visits and hospital admission rates after curative chemotherapy for breast cancer","volume":"11","author":"Pittman","year":"2015","journal-title":"J. Oncol. Pract."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.zefq.2022.01.002","article-title":"\u00d6konomische Aspekte bei der Versorgung von Patient*innen mit neuen oralen Tumortherapeutika: Erkenntnisse aus der AMBORA-Studie","volume":"169","author":"Schlichtig","year":"2022","journal-title":"Z. F\u00fcr Evidenz Fortbild. Und Qual. Im Gesundh."},{"key":"ref_24","unstructured":"(2022, March 05). National Cancer Institute: Common Terminology Criteria for Adverse Events (CTCAE). Version 4.03, Available online: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_50."},{"key":"ref_25","unstructured":"The Uppsala Monitoring Center (2022, June 05). The Use of the WHO-UMC System for Standardised Case Causality Assessment. Available online: https:\/\/cdn.who.int\/media\/docs\/default-source\/medicines\/pharmacovigilance\/whocausality-assessment.pdf?sfvrsn=5d8130bb_2&download=true."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1002\/1097-0258(20001215)19:23<3219::AID-SIM623>3.0.CO;2-P","article-title":"Analysis of cost data in randomized trials: An application of the non-parametric bootstrap","volume":"19","author":"Barber","year":"2000","journal-title":"Stat Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1136\/bmj.320.7243.1197","article-title":"How should cost data in pragmatic randomised trials be analysed?","volume":"320","author":"Thompson","year":"2000","journal-title":"BMJ"},{"key":"ref_28","first-page":"54","article-title":"Bootstrap methods for standard errors, confidence intervals, and other measures of statistical accuracy","volume":"1","author":"Efron","year":"1986","journal-title":"Stat. Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"eaan4368","DOI":"10.1126\/science.aan4368","article-title":"The target landscape of clinical kinase drugs","volume":"358","author":"Klaeger","year":"2017","journal-title":"Science"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/pds.3663","article-title":"Adverse drug events in patients admitted to an emergency department: An analysis of direct costs","volume":"24","author":"Meier","year":"2015","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1136\/ejhpharm-2019-001973","article-title":"Clinical pharmacy services in Germany: A national survey","volume":"28","author":"Schulz","year":"2021","journal-title":"Eur. J. Hosp. Pharm."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1177\/1078155220976801","article-title":"Impact of clinical pharmacy in oncology and hematology centers: A systematic review","volume":"27","author":"Oliveira","year":"2021","journal-title":"J. Oncol. Pharm. Pract."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/21\/6392\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:05:21Z","timestamp":1760144721000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/21\/6392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,28]]},"references-count":33,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["jcm11216392"],"URL":"https:\/\/doi.org\/10.3390\/jcm11216392","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,28]]}}}